HomeNewsBusinessMarketsSebi bans Nirman Agri Genetics for IPO fund diversion; alleges 93% fund diverted, halts corporate actions
Trending Topics

Sebi bans Nirman Agri Genetics for IPO fund diversion; alleges 93% fund diverted, halts corporate actions

Sebi initiated the examination as part of a broader review of IPOs handled by merchant banker First Overseas between May 2022 and April 2025, following irregularities found in the IPO of Synoptics Technologies Ltd. NAGL’s IPO is one of the issues scrutinised during this probe.

October 14, 2025 / 21:58 IST
Story continues below Advertisement

The Securities and Exchange Board of India (Sebi) has barred SME-listed Nirman Agri Genetics Ltd (NAGL) from accessing the securities market for alleged diversion of IPO funds. Sebi has also directed the company to halt all proposed corporate actions — including a bonus issue, stock split, and a name change to Agriicare Life Corp Ltd — until further orders.

In an interim order passed on Tuesday, Sebi Whole-Time Member Kamlesh Chandra Varshney also restrained the company’s promoter Pranav Kailas Bagal from buying, selling, or dealing in NAGL shares, directly or indirectly, till further directions.

Story continues below Advertisement

Sebi’s investigation found that the company had mis-utilised about Rs 18.89 crore, or 93 percent of the total IPO proceeds of Rs 20.30 crore, by transferring funds to entities that were either fictitious, suspect in nature, or controlled by Bagal and his relatives. The regulator noted that NAGL submitted conflicting information regarding fund utilisation without any credible explanation for the discrepancies.

Sebi order noted, “The Company has failed to furnish any credible proof of any agreement or invoices backing the transactions between the Company and the said parties. To top it all, in case of three entities to whom the Company claims to have made payment, the bank accounts where the payments were credited were found to be belonging to entirely different parties.”